Author

G. K. L. Chan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

A. Barpanda· 1 shared A. Diaz· 1 shared A. Du· 1 shared A. Saijo· 1 shared A. Wiita· 1 shared A. Yamamichi· 1 shared C. A. Klebanoff· 1 shared C. Hong· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Barpanda

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens

D. W. Kwok, N. O. Stevers, T. Nejo, L. H. Chen, I. Etxeberria, J. Jung, K. Okada, M. Colton Cove, S. Lakshmanachetty, M. Gallus, A. Barpanda, C. Hong, G. K. L. Chan, S. H. Wu, E. Ramos, , H. Okada

The paper identifies tumor-wide splicing aberrations that generate public neoantigens, enabling T-cell-based immunotherapies targeting intratumoral heterogeneity.

bioRxiv · Oct 19, 2023 · PreprintCancer Biology

Oncogenic PKA signaling stabilizes MYC oncoproteins via an aurora kinase A-dependent mechanism

G. K. L. Chan, S. Maisel, Y. C. Hwang, R. R. B. Wolber, P. Vu, K. C. Patra, M. Bouhaddou, H. L. Kenerson, R. S. Yeung, D. L. Swaney, N. J. Krogan, R. E. Turnham, J. D. Scott, K. J. Riehle, N. Bardeesy, J. D. Gordan

This study identifies two PKA-driven oncogenic mechanisms, showing AURKA stabilizes MYC oncoproteins through a PIM2-mediated feedback loop, and suggests CD-532 as a potential therapeutic target.

bioRxiv · Apr 16, 2021Cancer Biology